newsfilter
← Latest News
GlobeNewswire·

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that